论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Gao P, Zhao Z, Zhang C, Wang C, Long K, Guo L, Li B
Received 29 July 2018
Accepted for publication 15 October 2018
Published 13 November 2018 Volume 2018:12 Pages 3867—3878
DOI https://doi.org/10.2147/DDDT.S181798
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 3
Editor who approved publication: Prof. Dr. Cristiana Tanase
Purpose: Acute lung
injury (ALI) is a common and fatal oxidative stress in the lung, mainly induced
by endothelial injury and capillary leakage. In our previous study, “Fusu
agent”, a traditional Chinese medicine, was found to exert preventive effect on
endothelial damage in lipopolysaccharide (LPS)-induced ALI model rats partially
via inhibiting heparanase1 (HPA1) activation and inhibiting the inflammatory
factors. However, it is still unknown whether Fusu agent exerts its therapeutic
effect in LPS-induced ALI model rats and its potential mechanism.
Materials and methods: Rats were injected with LPS (3 mg/kg, intraperitoneally) to
induced ALI, and the prepared Fusu agent was given (2, 4 or 6 g/kg) 2 hours
after LPS challenge. Twenty-four or 48 hours after Fusu agent administration,
the biochemical changes in the plasma and lung tissues and the
morphological/histological changes in the lung associated with inflammation and
injury were evaluated. Human umbilical vein endothelial cells (HUVECs) were
employed to confirm the therapeutic effects of Fusu agent and investigate its
mechanisms, that is, affecting ROS accumulation, mitochondrial transmembrane
potential (MTP) maintenance and decreasing the expression levels of HPA1.
Results: Administration
of Fusu agent obviously improved the lung injury and recovered vascular
endothelium loss and injury. CD31 signal, which is a specific marker for
endothelial vascular lesions, was decreased after Fusu agent treatment in
LPS-induced ALI model rats, indicating its therapeutic effect against endothelial
surface layer injury. Meanwhile, Fusu agent also decreased HPA1 expression and
inflammatory responses. In vitro, Fusu agent-medicated serum decreased injury
and cell death induced by LPS in HUVECs by stabilizing MTP and decreasing the
leakage of lactate dehydrogenase. Consistently, Fusu agent-medicated serum
downregulated HPA1 induced by LPS stimulation.
Conclusion: These
findings suggest that Fusu agent exerts its therapeutic effect in both
LPS-induced ALI model rats and HUVECs potentially via suppressing HPA1
expression, and thus exerts prosurvival effect via maintaining MTP and
attenuating cell injury.
Keywords: ALI,
heparanase, mitochondrial transmembrane potential, HUVECs, acute lung injury,
ROS accumulation
